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the double bond between C4 and C5. 5a-dihydroprogesterone is then converted by 3a-hydroxysteroid dehydrogenase to allopregnanolone (3a,5a-tetrahydroprogesterone, ALLO) by changing the ketone group on C3 to an alcohol group. This step is reversible.
In the rat brain, most progesterone is metabolized to DHP within 10 minutes and DHP is metabolized to ALLO within 30 minutes [9] . Finasteride inhibits 5a-reductase [12] , whereas. Indomethacin and medroxyprogesterone acetate inhibit of3a-HSD [13] . These enzyme inhibitors play important roles in studies of the progesterone family ( Fig. 1 ).
Concentrations in body and brain
Concentrations of progesterone in the peripheral compartment vary widely in females during the estrous cycle, with lower levels and less variation being seen in males [14] . In the central compartment, progesterone and its metabolites fluctuate according to circadian rhythms [15] , as well as (in females) varying with the estrous cycle. These variations have profound effects on cognition and behavior [15, 16] . Endogenous progesterone and its 5a metabolites tend to accumulate in the brain [9, 17] , with the peak concentrations being much higher than concentrations in the periphery [15] .
Following exogenous administration, brain concentrations of progesterone are 3 times higher than concentrations in the periphery. After intravenous (IV) injections of progesterone and 5a-DHP in rats, for instance, both compounds are found to accumulate to high levels in the central department. The highest levels being found in the hypothalamus and anterior pituitary region, with very little being found in the cerebral cortex [9] .
A comprehensive review of progesterone's fate in the body may be found in Taraborrelli [18] and a comprehensive pharmacokinetic study is presented by Irwin et al. [17] .
4. Anti-seizure effects of progesterone 4.1. Animal studies Table 1 summarizes the studies done on progesterone in different animal seizure models. Seyle was perhaps the first to report the antiseizure effects of progesterone, administering progesterone to pentylenetetrazole (PTZ)-treated immature male rats in 1942 [19] . Later, these effects were confirmed by others, using both male and female animals, and in a variety of models, including the amygdala-kindling model [20] [21] [22] , the hippocampal-kindling model [23] , the PTZ model in mature rats [12, [24] [25] [26] , and the kainic acid model [27] . Most studies have reported an ED50 higher than 50 mg/kg, and have also reported sedation as a common side effect. In the kindling model, progesterone suppresses the generalized convulsions, but only partially suppresses focal discharge even at high doses [23] [28] .
Compared to the classical anti-seizure drugs, progesterone is not very potent. Akula et al. compared progesterone with other anti-seizure drugs in the intravenous PTZ model in mice and concluded that progesterone is more potent than tiagabine, GABA, adenosine, gabapentin and ethanol, but less potent than triazolam, clonazepam, diazepam, phenobarbital, carbamazepine and phenytoin [24] . Progesterone is also less potent than (+)MK-801 and diazepam in protecting against picrotoxin-, bicuculline-and NMDA-induced lethality [29] .
Progesterone has also shown pro-seizure effects in one animal [30] . The pro-seizure action was probably due to a progesterone metabolite, not to progesterone itself, since the effect was attenuated by blocking the 5a hydroxylation pathway with finasteride [31] . Progesterone's secondary metabolite, ALLO is a known GABA agonist [32] , and most GABA agonists exacerbate absence seizures [33] .
Clinical studies
Clinical studies with progesterone have usually been done in women with catamenial epilepsy. In "catamenial" epilepsy, seizures tend to cluster during specific phases of the menstrual cycles, such as ovulation and menstruation [35] . Herzog has proposed a scheme that classifies these seizures into 3 categories: 1) C1 or the "perimenstural" pattern involves seizures that occur around day 0 of menstrual cycle, a period that is characterized by low progesterone levels; 2) C2 or the "periovulatory" pattern involves seizures that occur around Day10-14 of the cycle, a period that corresponds to a physiological surge in estrogen and low progesterone; and 3) C3 or the "inadequate luteal" pattern involves seizures that occur in the luteal phase. Normally progesterone is high during this phase, but women with this pattern do not experience the normal progesterone surge, making their luteal phases "inadequate" [34] . Table 2 summarizes clinical studies on progesterone and its analogs as anti-seizure therapy. As an established contraceptive, progesterone has a number of commercially available analogs and formulationseach with a slightly different spectrum of activity and potencywhich has greatly facilitated the clinical studies of progesterone.
One of the first attempts to treat drug intractable epilepsy with a form of progesterone occurred in an 8 year old girl, who had frequent seizures prior to her menstrual period [35] . Zimmerman et al. reasoned that if it were possible to stop her menstrual cycle and it might also be possible stop her seizures. Medroxyprogesterone acetate (MPA), a potent contraceptive with the brand name Provera, was prescribed in both oral form and intramuscular injection. The girl remained seizure free during her 4-month treatment period [35] .
In the years after Zimmerman's first case report, many other openlabel add-on clinical trials have been conducted in women with catamenial seizures ( Table 2 ). Most clinical trials have reported a reduction in seizure frequency, with one notable exception. This was a clinical trial conducted by Dana-Haeri and Richens [36] . In the Dana-Haeri & Richens study, noresthisterone was prescribed as the progesterone-like compound. Noresthisterone is more potent than progesterone itself in terms of activating the progesterone nuclear receptors. Noresthisterone, however, was not effective. This failure may suggest that the progesterone nuclear receptor is not involved in producing progesterone's anti-seizure effects.
Following these open label studies, a full-scale, double-blind, placebo-controlled randomized clinical trial (RCT)-a "gold standard" trial was finally done in 2012. In that trial, Herzog et al. recruited 294 female patients with intractable partial seizures, with or without catamenial exacerbation [37] . In this fully controlled trial, there was no overall difference in responding between the treatment and control groups. A post-hoc analysis, however, revealed that patients those with catamenial epilepsy and severe perimenstrual exacerbations (C1) did benefit from progesterone therapy [38] .
Subsequently, a second double-blind, placebo-controlled clinical study was conducted by Najafi's at al. This trial, which involved only women with catamential seizures, also showed a statistically significant reduction in seizure frequency in the progesterone treated group [38] . In clinical studies, therefore, it appears that progesterone benefits women with catamenial seizures, but not necessarily women with other types of epilepsy.
Anti-seizure effects of allopregnanolone
It has been known for some time that the anti-seizure effects of progesterone are largely mediated by its metabolites. In animal studies, when the 5a metabolism of progesterone is blocked by finasteride, the anti-seizure effect of progesterone is nearly abolished [12, 39] . There is also a clinical report where a woman who had good seizure control on progesterone relapsed when the doctor prescribed her finasteride. Finasteride was later removed from her treatment and she achieved good seizure control on progesterone again [40] .
The metabolite that has been most extensively studied is allopregnanolone (ALLO), progesterone's secondary metabolite 5.1. Animal studies Table 3 summarizes the animal studies that have examined the antiseizure effects of, ALLO in animal seizure models. As indicated, ALLO suppresses generalized convulsive seizures in the PTZ model [26, 41] , the kainic acid model [27] and the 6 Hz model [42] . It also alleviates kainic acid and pilocarpine induced-status epilepticus in mice [43] and suppresses the secondarily generalized convulsive seizures in the rat amygdala kindling model [20, 44] and the mouse hippocampus kindling model [23] . (Focal kindled seizures are discussed below.) The reported ED50s have varied, but most studies have reported ED50s below 20 mg/ kgconsiderably lower than the ED50s reported for progesterone in animal studies, Side effects, especially sedation, have been reported even at these lower doses.
ALLO is relatively potent as compared to other anti-seizure drugs. Taubøll & Gjerstad compared ALLO's and phenobarbital's effects on recurrent inhibition in rat hippocampal slices, and concluded that ALLO was the most potent of the three [45] . ALLO is also more potent than 5β-tetrahydrodeoxycortisone and (+)MK-801 against picrotoxin-and bicuculline-induced seizures in male albino mice [29] .
ALLO, however, has not proven to be effective in all models of generalized seizures. It has failed to suppress tonic hindlimb extension in the maximal electroshock model' [41] . It also exacerbates the absence seizures modeled by the WAG/Rij rats [31] .
ALLO has produced apparently conflicting results when tested against limbic focal seizures in kindled subjects. Limbic focal seizures in kindled animals are thought to model drug-resistant complex-partial seizures in humans [28] and, therefore, the suppression of limbic focal seizures in kindled animals is of great interest to drug development. Jeffrey et al. reported that ALLO suppressed focal hippocampal afterdischarges in mice [23] . Jeffrey et al., however, were measuring afterdischarge duration rather than the complete suppression of afterdischarge. Lonsdale, who used a stricter criterionthe complete suppression of the focus rather than the shortening of afterdischargereported no focal seizure suppression in the amygdala-kindled ratsor less than 40% of suppression at a very high [20, 44] . These differing results clearly relate to the criteria used. Jeffery et al. would have reported no suppression of focal seizures if she had used Lonsdale's criterion [46] . Table 4 presents a summary of the clinical trials using ALLO and its commercial analog ganaxolone. Clinically, ALLO seems to have been tested for only one particular indication, super-refractory status epilepticus (SRSE). SRSE occurs when status epilepticus has resisted all of the standard medications, and has even resisted general anesthesia. It is diagnosed when status is uncontrolled 24 hours after initiating anesthetic treatment [47] . Case reports indicate that intravenous ALLO effectively suppresses SRSE in both adults [48] and paediatric patients [49] . Recently, a commercial aqueous formulation of ALLObrexanolonehas been tested in an open-label add-on clinical trial in SRSE patients, and has proved successful in 77% of patients [50] . However, Table 2 Progesterone and its analogs as anti-seizure drugs in clinical studies. RCT: randomized clinical trials, P.O.: oral route, I.M.: intramuscular injection, I.V.: intravenous injection, BID: twice daily, TID: three times daily. Table 3 Allopregnanolone due to the small sample size in this open trial, some caution must be applied. It will be better to wait for the results from the randomized double-blind placebo-controlled Phase III trial which is currently underway (NCT02477618, N = 132) before drawing any firm conclusions. ALLO also has a commercially available analog, ganaxolone, whose chemical structure differs by only one methyl group on C3 [32] . This methyl substitution prolongs ALLO's half-life without diminishing its potency. Most clinical trials, therefore, have been conducted with ganaxolone rather than with ALLO. All of the findings of these trials have been positive, indicating that ganaxolone has good anti-seizure effects in people with epilepsy. Since ganaxolonelike ALLOis a potent GABA-A agonist [32] , it is not surprising that the side effects have included fatigue and sedation.
Clinical studies
It is worth noting that both male and female subjects have been recruited in ganaxolone trials, whereas only females have been recruited in progesterone trials. ALLO, unlike progesterone, has no hormonal effects [51] .
Anti-seizure effects of 5a-dihydroprogesterone
Following the early finasteride experiments, attention centered on progesterone's secondary metabolite ALLOa known GABA agonist. Finasteride, however, blocks the synthesis of both DHP and A LLO. It was possible, therefore, that DHP might also be contributing to progesterone's anti-seizure effects. In fact, progesterone still has strong anti-seizure effects when co-administered with indomethacin, which blocks the formation of ALLO [52] . This suggested that DHP itself had anti-seizure effects and led to the further study of DHP.
DHP has been far less studied than progesterone or ALLO. No clinical studies have as yet been done with DHP, so only animal studies will be discussed here. Table 5 summarizes the animal studies on DHP. Landgren et al. actually first described the anti-seizure effects of DHP in penicillin-induced seizures in ovariectomized cats in the 1980s [53] .
Animal studies
There was little subsequent research in this field, however, until Lonsdale and collaborators returned to this area in 2003. They reported that subcutaneous DHP suppressed both focal seizures and secondarily generalized motor seizures in amygdala-kindled rats. Suppression was found at non-sedating doses and it occurred in both males [20] and females [21] . Of particular interest was the suppression of the amygdala focus at non-toxic doses.
Not all subsequent studies, however, have supported Lonsdale's work. Jeffrey, for instance, reported that intraperitoneal DHP had no effect of focal or generalized seizures in hippocampal-kindled mice [46] . It is hard to compare Lonsdale's and Jeffrey's studies, however, since they differed in the animal species, the kindling site and the route of administration. There is also the question of solubility, since DHP has a high partition coefficient and is very hard to keep in solution.
A recent study by Wu & Burnham has switched to the intravenous route of injection, which allows for the use of lower doses which are easier to keep in solution [54] . Female Wistar rats were implanted with an electrode in the right basolateral amygdala. They were then kindled to 15 stage 5 seizures, stability tested, and cannulated in the jugular vein. Multiple doses of IV DHP were tested against focal electrographic seizures and secondarily generalized convulsions. A dose-dependent suppression of both generalized and focal seizures was found, with ED50s of 1.69 mg/kg for the generalized convulsive seizures and of 3.48 mg/kg for the focal electrographic seizures. Ataxia, as rated by the Löscher ataxia scale, was also seen, and had a TD50 of 3.57 mg/kg. These effects were seen almost immediately, and lasted to about 60 minutes post-injection [54] . These data confirm the ability of DHP to suppress the drug-resistant amygdala focus in kindled animals. Future Table 4 Allopreganolone and its analog ganaxolone as anti-seizure drugs in clinical studies, listed in chronological order. [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] studies will have to address the question of why ataxia was seen in the Wu et al. studies but not in Lonsdale's previous intraperitoneal studies.
The different routes of injection may offer an explanation.
Possible mechanisms: progesterone, ALLO and DHP

Progesterone
Progesterone itself seems to have some anti-seizure actions, in addition to the anti-seizure actions of its metabolites. These may be seen in the presence of finastreride pretreatment, but they occur at high and sedating doses [23] Progesterone has several molecular targets in the central nervous system which might mediate these actions. These include both genomic progesterone receptors [55] and non-genomic receptors [56] . The nongenomic receptors include: 1) the membrane progesterone receptor (mPRs)the G-protein coupled receptors; 2) progesterone membrane receptor components (PGMRCs); and 3) sigma receptors.
Since progesterone's anti-seizure effects can be seen shortly after administration, they presumably relate to its binding to non-genomic receptors. In fact, progesterone's anti-seizure actions are preserved even when nuclear progesterone receptor is antagonized by RU486 [12] or in mice where the nuclear receptors have been knocked-out [26] .
The fact that progesterone's ED50 in animals is quite high (over 50 mg/kg), and that it loses much of its potency in the presence of finasteride [39] suggests that progesterone's low-dose anti-seizure effects are largely mediated by its active metabolites.
ALLO
ALLO is considerably more potent than progesterone, with an ED50 below 20 mg/kg in animal seizure models. Since its anti-seizure actions appear shortly after administration (Table 3) , it also presumably works on non-genomic receptors. Similar to barbiturate, ALLO is also a positive allosteric modulator of the cell-surface GABA-A receptor [57] . At nM concentrations, ALLO enhances GABA's ability to open chloride channels [58] , and at higher concentrations, ALLO opens the GABA-A related chloride channel even in the absence of GABA. As expected, sedation and ataxia are common side effects of ALLOand its analog ganaxoloneas they are with other GABA-enhancing drugs [59] .
ALLO is also an agonist at cell-surface mPRs in GT17 neuronal cell lines [60] which may partially contribute to its anti-seizures effects. It does not bind to nuclear progesterone receptors (nPRs) [61] .
DHP
DHP is also more potent than progesterone, with an ED50 in intravenous studies below 5 mg/kg. Once again its anti-seizure effects are seen shortly after administration suggesting that they are mediated by non-genomic receptors.
The mechanisms of DHP's actions have been little studied as yet. Binding studies, however, have revealed that DHP binds to both mPRs and nPRs. Its affinity for mPRs is stronger than its affinity for nPRs [62, 63] . It does bind to nPRs, however, with an affinity that is weaker than progesterone, but stronger than ALLO [64, 65] . Binding to nPRs probably doesn't contribute to its (very rapid) anti-seizure effects, but might be a source of hormonal side effects if DHP were developed as an anti-seizure drug.
DHP also binds to PGMRCs [56, 66] . Little is understood of the function of PGMRC receptors [67] . They are hypothesized to participate in cholesterol synthesis, to modulate cell cycling, and to direct axonal migration during brain development. It seem unlikely that any of these actions would contribute to DHP's rapid anti-seizure effects, but, once again, they might be a source of side effects if DHP were developed as a drug. In addition to their acute anti-seizure actions, compounds in the progesterone family might also alleviate difficult-to-treat seizures by modulating neuroinflammation. Both systemic and CNS inflammatory markers are elevated in drug-resistant seizure disorders such as West syndrome (infantile spasms), viral encephalitis-induced epilepsy [68] , drug-resistant temporal lobe epilepsy [69] , and status epilepticus [70] . These include markers such as IL-1B, IL-6, TNFa [71] and NF-kB [72] .
There is some evidence that progesterone, DHP and ALLO may all attenuate inflammatory responses. The evidence is strongest for progesterone. In a model of early brain injury, for instance, progesterone ameliorates the elevation of NF-kB pathway and other inflammatory markers. It has also shown anti-inflammatory effects in animal models of traumatic brain injury and stroke [73] . In a recent study, progesterone decreased both systemic and central inflammation cytokinessuch as IL-1B, IL-6, and TNFain a model of neonatal arterial ischemic stroke. It also decreased stroke-induced seizure occurrence and severity [71] .
ALLO has similarly been shown to reduce the expression of cytokines such as TNF-a, IL-8, and IL-1b in an in vitro model [74] , and both progesterone and ALLO reduce IL-1b and TNF-a in the acute phase of traumatic brain injury in rats [75, 76] .
There is less evidence for DHP. DHP, however, at 0.25-0.5 mg/kg has been shown to reduce hilar neuron loss and vimentin expression in reactive astrocytes in the kainic-acid model [77] .
As with progesterone's anti-seizure effects, progesterone's anti-inflammatory and neuroprotective effects may mainly relate to its metabolites. When 5a-reductase is blocked by finasteride, progesterone's neuroprotective effects are abolished [78] . Interestingly, when indomethacin is used to block the interconversion between DHP and ALLO, both DHP and ALLO's neuroprotective effects are equally diminished. A possible explanation is that both DHP and ALLO are required to provide neuroprotection [78] .
The anti-inflammatory actions of the progesterone family, and the possible anti-seizure effects of anti-inflammatory compounds, warrant further investigation.
Directions for future drug development
Compounds in the progesterone family have proven their anti-seizure effects in both animal and clinical studies. Some are anti-seizure at non-sedating doses, and appear to suppress even pharmacoresistant limbic seizures. ALLO has already been developed as the anti-seizure compound ganaxolone [32] , but DHP has not yet been exploited.
Progesterone and its 5a metabolites, however, have some side effects that would need to be reduced through rational drug designespecially for long-term use. First, progesterone itself suppresses the fertility cycle in females, which is why progesterone-related compounds are widely used as contraceptives [79] . In male sex offenders, the progesterone analog medroxyprogesterone acetate has been used to reduce sexual arousal. In this population, MPA lowered testosterone and luteinizing hormone levels, as well as decreased testicular size [80] . These hormone effects, mediated via intracellular receptors, would need to be reduced in drugs directly based on progesterone.
DHP, like progesterone, might also affect the female reproductive cycle. Direct evidence is lacking, but indirect evidence suggests that DHP affects the secretion of luteinizing hormone [81] and follicle stimulating hormone (FSH) [82] . In addition, DHP induces inducing lordosis in female Sprague-Dawley rats [83] . Krebs et al. have suggested that this effect may be regulated by PGMRC1 [84] . Similarly, chronic administration of DHP at 500ug to estrogen-primed, ovariectomized female mice increases receptively in a strain-dependent manner [85] . It has been found that this DHP-induced receptivity in a dominant trait in mice [86] .
ALLO, on the other hand, has negligible affinity to the nPR receptor under physiological conditions [65] . These results must be interpreted with caution, however, ALLO's possible effects on the reproductive and other systems should not be overlooked [87] . ALLO suppresses the stress response, for instance, by modulating the hypothalamus-pituitary-adrenal axis [88] . Upregulated ALLO during late pregnancy is crucial in maintaining the hypo-responsiveness to stress, a mechanism independent of progesterone and DHP [89] . Acute, intracerebroventricular administration of 6uM ALLO also alters luteinizing hormone, progesterone and prolactin levels [90] and inhibits lordosis, therefore decreasing sexual receptivity [91] . ALLO also affects feeding behavior via central mechanisms. Repeated exposure to ALLO at 10-20 mg/kg daily increases food intake and promotes weight gain in rats [92, 93] . In humans, high levels of ALLO are correlated with weight gain in pregnancy and in those with polycystic ovarian disease [94] .
Tumorigenesis in mammary tissues is another possible effect of both progesterone and DHP. Wiebe's group has proposed that DHP in particular promotes cellular proliferation and decreases cell adhesion based on in vitro studies [95, 96] . DHP has also been shown to promote the neoplastic transformation of non-tumor C4HD murine mammary cells in vivo [97] .
It seems, however, that DHP stimulates tumorigenesis via mitogenactivated protein kinase (MAPK) pathway which is activated by mPRs. MPRs seem to have little roles in suppressing limbic seizures [97] . Thus, it might be possible to develop an analog that lack mPR activity while maintaining anti-seizure effects.
If DHP were to be developed as an anti-seizure agent, both its hormonal and turmorigenic effects would have to be reduced through rational drug design.
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